Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort.

"The authors of this paper include an Associate Editor and Editorial Board Member of Therapeutic Advances in Respiratory Disease. Therefore, the peer review process was managed by alternative members of the Editorial Board and the submitting Editors had no involvement in the decision-making process."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: COSYCONET is supported by the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET) and performed in collaboration with the German Center for Lung Research (DZL). The project is funded by the BMBF with grant number 01 GI 0881, and is supported by unrestricted grants from AstraZeneca GmbH, Bayer Schering Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Chiesi GmbH, GlaxoSmithKline, Grifols Deutschland GmbH, MSD Sharp & Dohme GmbH, Mundipharma GmbH, Novartis Deutschland GmbH, Pfizer Pharma GmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Teva GmbH for patient investigations and laboratory measurements. For the present study, an additional grant for data management was given by Novartis Pharma GmbH. The funding body had no involvement in the design of the study, or the collection, analysis or interpretation of the data."

"Trial registration: ClinicalTrials.gov NCT01245933."